Compliance with Russia's "most complex" track and trace requirements given a boost
By 2020, all medicines imported into and traded within Russia must comply with Russian Federal Law No. 425-FZ.
TraceLink has announced a partnership with Excellis Health Solutions to provide local implementation services for TraceLink’s Russia compliance solution, helping pharmaceutical companies easily engage with their local Russia teams and comply with the Russian track and trace requirements.
Under Russian Federal Law No. 425-FZ, pharmaceutical companies are required to manage serialization and traceability of medicines from manufacturer to patient, and report product and transaction events to the central government system. By 2020, all medicines imported into and traded within Russia must comply with the regulation, applying to over 370 manufacturers supplying medicines within, and into the Russian market. A recent TraceLink poll showed that 82% of respondents with Russian track and trace requirements feel that Russia’s compliance regulations are more complex than any other country.
“For pharmaceutical companies complying with the complicated Russian requirements, TraceLink not only provides them with a locally implemented, global compliance platform that orchestrates compliance-related business processes between their partners, but a solution that is also agile enough to adapt to the continuous changes and evolution of the Russian law by leveraging existing integrations done with previous markets,” said Shabbir Dahod, president and CEO, TraceLink. “Furthermore, our partnership with Excellis will allow TraceLink to service the needs of the Russian market with local subject matter expertise and resources in the native Russian language, creating the best possible experience for our customers while ensuring both global and local in-market support.”
“Our partnership with Tracelink will allow pharmaceutical companies to leverage Excellis’ industry-leading subject matter expertise and a comprehensive, yet easy to manage, global compliance solution, in order to successfully meet the Russian requirements on time,” said Karan Narang, President, International at Excellis Health Solutions, an international consulting firm focused on providing track and trace implementation services in the pharmaceutical supply chain. “Excellis is already a strategic partner with Tracelink and we look forward to increased collaboration to provide local access and support to the Russian market.”
Built on TraceLink’s existing network tenant platform and instrumented with the core serialization, master data, integration, and compliance functionalities seen in all other TraceLink compliance solutions, the Russia solution is designed to meet the complex data choreography requirements for Russia compliance, TraceLink’s pre-configurable workflows and application logic enable companies to report on serialized events, and manage import, export, receipt, transfer, and shipment processes.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance